This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
indicated that a sample size of 200 preterm infants was required to ensure 80% power with a significance level of 0.05. The sample was selected by including infants admitted to eligible hospitals. A hospital was eligible if it was accustomed to providing long-term ventilatory support for newborn infants, had facilities to provide iNO, and had research ethics committee approval to participate. There were no reports of refusal to participate.
Study design
The authors designed a randomised controlled trial across 15 neonatal units in Ireland and the UK. Clinicians and parents were not blinded to the allocated group although, where possible, outcomes were assessed without knowledge of either the randomised or actual treatment. The infants were followed for 1 year. Sixty-four patients died before follow-up and one patient was lost to formal follow-up.
Analysis of effectiveness
The analysis was based on intention to treat principles. Three infants randomised to iNO did not receive iNO (died before administration), while 4 patients randomised to not receive iNO did receive iNO (all 4 of whom later died). The primary health outcomes were assessed at discharge from neonatal services (or prior death) and at 1 year corrected age. The outcomes assessed were death or severe disability at 1 year corrected age (assessed individually and as a composite measure) and death before discharge or chronic lung disease. The infants in the two groups were compared extensively at baseline in terms of their demographic and clinical variables. Infants in the iNO group were reported to be of higher birth weight and more mature but were otherwise comparable to infants in the no iNO group.
Effectiveness results
The relative risk of death or severe disability at 1 year corrected age was 0.99 (95% confidence interval, CI: 0.76 to 1.29; p=0.94).
The relative risk of death or supplemental oxygen on expected date of delivery was 0.84 (95% CI: 0.68 to 1.02; p=0.08).
The relative risk of death was 0.85 (95% CI: 0.62 to 1.16; p=0.30).
Clinical conclusions
The authors concluded "there was no evidence of an effect of iNO on any of the pre-specified primary outcomes: death or severe disability at 1 year corrected age".
Measure of benefits used in the economic analysis
The authors did not estimate a summary measure of health benefit. The study was, in effect, a cost-consequences analysis.
Direct costs
A perspective for the cost analysis was not reported, although the authors noted that costs to a range of agencies were included. The principle elements included in the analysis were length of stay in the hospital, length of time on supplemental oxygen, and length of time on ventilatory support. These data were collected for the first stay in hospital on specially designed data collection sheets. Data concerning health and community service use and costs to parents between discharge home and 1 year corrected age were obtained from cross-sectional questionnaires completed by parents at 6-monthly intervals. The unit costs were taken from the National Health Service reference costs database and from published sources. The price year was 2002/03. Discounting was not required because of the relatively short time horizon of the study. Missing data from parent report forms were assumed to have the mean value of community costs from the survivors from the treatment or control groups.
